331 related articles for article (PubMed ID: 2131793)
1. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
[TBL] [Abstract][Full Text] [Related]
2. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
Durie BG; Dixon DO; Carter S; Stephens R; Rivkin S; Bonnet J; Salmon SE; Dabich L; Files JC; Costanzi JJ
J Clin Oncol; 1986 Aug; 4(8):1227-37. PubMed ID: 3525768
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
[TBL] [Abstract][Full Text] [Related]
5. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
6. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Gyllenhammar H; Johansson B; Juliusson G; Järnmark M
Eur J Haematol; 1989 Jul; 43(1):54-62. PubMed ID: 2670605
[TBL] [Abstract][Full Text] [Related]
7. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
8. Consolidation hemibody radiotherapy following induction combination chemotherapy in high-tumor-burden multiple myeloma.
MacKenzie MR; Wold H; George C; Gandara D; Ray G; Schiff S; Shields J; Artim R; Davidson H; Meyers F
J Clin Oncol; 1992 Nov; 10(11):1769-74. PubMed ID: 1403058
[TBL] [Abstract][Full Text] [Related]
9. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
Bladé J; San Miguel JF; Fontanillas M; Esteve J; Maldonado J; Alcalá A; Brunet S; García-Conde J; Besalduch J; Moro MJ; Fernández-Calvo J; Conde E; Font L; Gardella S; Carnero M; Carbonell F; Martí JM; Hernández-Martín J; Ortega F; Besses C; Ribera JM; Trujillo J; Escudero ML; Rozman C; Estapé J; Montserrat E
Hematol J; 2001; 2(4):272-8. PubMed ID: 11920260
[TBL] [Abstract][Full Text] [Related]
10. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
[TBL] [Abstract][Full Text] [Related]
11. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H
Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
13. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
[TBL] [Abstract][Full Text] [Related]
14. Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
Cohen HJ; Bartolucci AA; Forman WB; Silberman HR
J Clin Oncol; 1986 Jun; 4(6):888-99. PubMed ID: 3519879
[TBL] [Abstract][Full Text] [Related]
15. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
16. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
[TBL] [Abstract][Full Text] [Related]
17. A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
Bladé J; San Miguel J; Alcalá A; Maldonado J; García-Conde J; Moro MJ; Sanz Sanz MA; Alonso C; Zubizarreta A; Besses C
Blut; 1990 Jun; 60(6):319-22. PubMed ID: 2198075
[TBL] [Abstract][Full Text] [Related]
18. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
Wutke K; Anger G
Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
[TBL] [Abstract][Full Text] [Related]
19. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Bladé J; Rosiñol L; Sureda A; Ribera JM; Díaz-Mediavilla J; García-Laraña J; Mateos MV; Palomera L; Fernández-Calvo J; Martí JM; Giraldo P; Carbonell F; Callís M; Trujillo J; Gardella S; Moro MJ; Barez A; Soler A; Font L; Fontanillas M; San Miguel J;
Blood; 2005 Dec; 106(12):3755-9. PubMed ID: 16105975
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
